Befiradol

Befiradol

Clinical data
ATC code	none
Legal status
Legal status	In general: uncontrolled
Identifiers
IUPAC name 3-chloro-4-fluorophenyl-[4-fluoro-4-([(5-methylpyridin-2-yl)methylamino]methyl)piperidin-1-yl]methanone
CAS Number	208110-64-9 N
PubChem CID	9865384
IUPHAR/BPS	3925
ChemSpider	8041076 Y
UNII	RAT9OHA1YH
ChEMBL	CHEMBL45305 Y
Chemical and physical data
Formula	C20H22ClF2N3O
Molar mass	393.857 g/mol
3D model (Jmol)	Interactive image Interactive image
SMILES n2cc(C)ccc2CNCC(F)(CC3)CCN3C(=O)c(cc1Cl)ccc1F FC2(CCN(C(=O)c1ccc(F)c(Cl)c1)CC2)CNCc3ncc(cc3)C
InChI InChI=1S/C20H22ClF2N3O/c1-14-2-4-16(25-11-14)12-24-13-20(23)6-8-26(9-7-20)19(27)15-3-5-18(22)17(21)10-15/h2-5,10-11,24H,6-9,12-13H2,1H3 Y Key:PKZXLMVXBZICTF-UHFFFAOYSA-N Y
NY (what is this?)

Befiradol (F-13,640; NLX-112) is a very potent and highly selective 5-HT_1A receptor full agonist. It has powerful analgesic and antiallodynic effects comparable to those of high doses of opioid painkillers, but with fewer and less prominent side effects, as well as little or no development of tolerance with repeated use. A SAR study revealed that replacement of the dihalophenyl moiety by 3-benzothienyl increases maximal efficacy from 84% to 124% (Ki=2.7 nM).

Befiradol was discovered and developed by Pierre Fabre Médicament, a French pharmaceuticals company. In September 2013, befiradol was out-licensed to Neurolixis, a California-based biotechnology company. Neurolixis announced that it intends to re-purpose befiradol for the treatment of Levodopa-induced dyskinesia in Parkinson's disease. In support of this indication, preclinical data was published describing the activity of befiradol in animal models of Parkinson's disease.